Low-molecular-weight heparins: potential treatment for feline heart disease

Winn Funded Research

 

Alwood, A. J., A. B. Downend, et al. (2007). “Anticoagulant effects of low-molecular-weight heparins in healthy cats.” J Vet Intern Med 21(3): 378-387.

Low-molecular-weight heparin (LMWH) has potential benefit in cats at risk for thromboembolic disease, such as cats with severe hypertrophic cardiomyopathy (HCM). However, LMWH pharmacokinetics has not been characterized in the cat. Cats have rapid absorption and elimination kinetics with LMWH therapy. On the basis of pharmacokinetic modeling, cats will require higher dosages and more frequent administration of LMWH to achieve human therapeutic anti-factor Xa activity of 0.5-1 U/mL.

>> PubMed abstract